Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis D
Biotech
Vir’s ph. 3 hepatitis delta win fuels push to eclipse Gilead
The phase 3 win in chronic hepatitis delta gives the biotech the first piece of the package it needs to file for FDA approval next year.
Nick Paul Taylor
Nov 9, 2026 6:20am
Mirum posts ph. 3 hepatitis win for challenger to Gilead, Vir
Sep 28, 2026 9:36am
Labcorp launches new hepatitis D test
Aug 25, 2026 1:22pm
Vir links up with Norgine in €550M hepatitis D licensing deal
Dec 17, 2025 12:50pm
Mirum nets Bluejay and its ph. 3-stage hepatitis drug for $620M
Dec 8, 2025 9:45am
Vir won't advance potential hep B 'cure' without a partner
Feb 27, 2025 11:37am
